Gogolox

Gogolox is an oral medication that contains the mucolytic agent Ambroxol Hydrochloride; the specific strength and dosage form are not detailed in the public data. Marketed in the European Union, it belongs to the respiratory system therapeutic class and is classified under ATC code R05CB01. The product is intended to aid the clearance of bronchial mucus in various respiratory conditions and improve patient comfort during illness.

Gogolox is indicated for use in respiratory conditions where thick or tenacious mucus impairs airway clearance.

- Cough associated with acute upper or lower respiratory tract infections. - Facilitation of mucus clearance in chronic bronchitis. - Adjunct therapy for patients with asthma experiencing productive cough. - Supportive treatment in COPD exacerbations with increased sputum viscosity. - Management of mucus retention following inhalation injuries.

The safety profile of Ambroxol Hydrochloride, the active component of Gogolox, includes both frequent and rare adverse events.

Common: - Mild gastrointestinal discomfort such as nausea or dyspepsia. - Transient skin rash or pruritus. - Taste alteration or mild oral irritation. - Headache.

Serious: - Allergic reactions including angioedema or anaphylaxis. - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic enzyme elevation in susceptible individuals.

When considering Gogolox, healthcare providers should evaluate several precautionary factors to ensure safe use.

- Assess for known hypersensitivity to Ambroxol or related compounds. - Use cautiously in patients with hepatic impairment. - Monitor renal function in individuals with severe kidney disease. - Pregnancy and lactation status should be reviewed, as safety data are limited. - Avoid use in children under the age specified by local regulations. - Consider potential interactions with other mucolytics or expectorants.

Gogolox may interact with other medicines; understanding these interactions helps minimize adverse effects.

Avoid: - Concurrent use with other mucolytic agents such as carbocisteine or N‑acetylcysteine. - Co‑administration with drugs that may cause bronchospasm in susceptible patients.

Use with caution: - Anticoagulants, as Ambroxol may enhance bleeding risk. - Bronchodilators, to monitor for additive respiratory effects. - Antihistamines, due to possible increased sedation.